Peter Buggisch Selected Research

Viremia

3/2013	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
12/2011	The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.
8/2009	Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
8/2009	Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.
4/2006	Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Buggisch Research Topics

Disease

43	Infections 01/2022 - 01/2006
26	Chronic Hepatitis C 01/2022 - 06/2003
21	Fibrosis (Cirrhosis) 05/2023 - 05/2008
21	Hepatitis C 01/2022 - 02/2006
7	Chronic Hepatitis B 01/2023 - 09/2006
7	Liver Diseases (Liver Disease) 01/2022 - 01/2006
6	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 09/2008
5	Viremia 03/2013 - 04/2006
4	Virus Diseases (Viral Diseases) 01/2021 - 01/2018
3	Pruritus (Itching) 02/2024 - 02/2012
3	HIV Infections (HIV Infection) 05/2023 - 01/2006
3	Hepatocellular Carcinoma (Hepatoma) 04/2023 - 01/2013
2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 02/2024 - 10/2017
2	Hepatitis D 04/2023 - 10/2011
2	Hepatitis B 01/2023 - 12/2019
2	Alcoholism (Alcohol Abuse) 01/2021 - 05/2008
2	Mental Disorders (Mental Disorder) 01/2021 - 07/2012
2	Disease Progression 12/2019 - 01/2013
2	Coinfection 05/2008 - 11/2006
2	Acquired Immunodeficiency Syndrome (AIDS) 05/2008 - 11/2006
2	Persistent Infection 09/2006 - 02/2006
1	Chronic Hepatitis D 04/2023
1	End Stage Liver Disease 04/2023
1	Hepatitis 04/2023
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2021
1	Major Depressive Disorder (Major Depressive Disorders) 01/2021
1	Depressive Disorder (Melancholia) 01/2021
1	Weight Loss (Weight Reduction) 12/2020
1	Chronic Renal Insufficiency 11/2019
1	Peptic Ulcer (Peptic Ulcers) 01/2019
1	Gastroesophageal Reflux (GERD) 01/2019
1	Dyspepsia (Indigestion) 10/2017
1	Spasm (Spasms) 10/2017
1	Dizziness (Lightheadedness) 10/2017
1	Myalgia 10/2017
1	Nausea 10/2017
1	Alcoholic Liver Diseases (Alcoholic Liver Disease) 03/2016

Drug/Important Bio-Agent (IBA)

30	Antiviral Agents (Antivirals)IBA 01/2022 - 06/2003
21	Ribavirin (Virazole)FDA LinkGeneric 01/2021 - 06/2003
17	InterferonsIBA 04/2023 - 12/2003
9	SofosbuvirIBA 11/2019 - 01/2014
9	RNA (Ribonucleic Acid)IBA 11/2018 - 04/2006
8	Interferon-alpha (Interferon Alfa)IBA 01/2021 - 01/2006
7	Alanine Transaminase (SGPT)IBA 04/2023 - 12/2011
6	Hepatitis B e AntigensIBA 01/2023 - 01/2006
6	sofosbuvir drug combination ledipasvirIBA 01/2021 - 05/2014
6	SimeprevirIBA 05/2019 - 01/2017
5	Tenofovir (Viread)FDA Link 10/2019 - 12/2008
5	peginterferon alfa-2a (Pegasys)FDA Link 10/2015 - 11/2006
4	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2008
4	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 03/2012
4	NucleotidesIBA 01/2017 - 01/2010
3	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2022 - 01/2020
3	paritaprevirIBA 11/2019 - 01/2019
3	ombitasvirIBA 05/2019 - 01/2018
3	daclatasvirIBA 05/2019 - 01/2017
3	ledipasvirIBA 11/2018 - 05/2014
3	peginterferon alfa-2b (Pegintron)FDA Link 06/2013 - 09/2011
3	NucleosidesIBA 03/2012 - 01/2006
3	Amantadine (Aman)FDA LinkGeneric 11/2008 - 06/2003
2	seladelparIBA 02/2024 - 10/2017
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2023 - 09/2006
2	CytokinesIBA 01/2021 - 10/2011
2	Ritonavir (Norvir)FDA Link 11/2019 - 02/2017
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2017
2	velpatasvirIBA 01/2019 - 01/2017
2	adefovirIBA 03/2012 - 09/2006
2	CholesterolIBA 12/2011 - 05/2008
2	adefovir dipivoxil (Hepsera)FDA Link 01/2011 - 12/2008
1	Alkaline PhosphataseIBA 02/2024
1	bulevirtideIBA 04/2023
1	EnzymesIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2020
1	Ferritins (Ferritin)IBA 12/2020
1	Fetal Proteins (Fetoprotein)IBA 09/2020
1	elbasvirIBA 07/2020
1	grazoprevirIBA 07/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Aspartic Acid (Aspartate)FDA Link 12/2019
1	Cytochrome P-450 CYP2B1 (PROD)IBA 05/2019
1	dasabuvirIBA 05/2019
1	Antipsychotic Agents (Antipsychotics)IBA 01/2019
1	odalasvirIBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2017
1	RHO(D) antibody (anti-D)IBA 10/2017
1	Interferon LambdaIBA 10/2017
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2017
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2017
1	GSK2336805IBA 02/2017
1	27- cyclohexyl- 12,13,16,17- tetrahydro- 22- methoxy- 11,17- dimethyl- 10,10- dioxide- 2,19- methano- 3,7:4,1- dimetheno- 1H,11H- 14,10,2,9,11,17- benzoxathiatetraazacyclo docosine-8,18(9H,15H)-dioneIBA 02/2017
1	voxilaprevirIBA 01/2017
1	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2017
1	Transaminases (Aminotransferases)IBA 03/2016

Therapy/Procedure

36	Therapeutics 01/2022 - 06/2003
4	Opiate Substitution Treatment 05/2023 - 01/2018
3	Duration of Therapy 01/2014 - 04/2006
2	Aftercare (After-Treatment) 01/2018 - 08/2007
1	Retreatment 01/2021